• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

pancreatic cancer

Incyte
Biotech

ESMO: Incyte claims ‘neck and neck’ KRAS G12D race with RevMed

Incyte has unveiled phase 1 data suggesting its KRAS G12D inhibitor could rival RevMed’s contender in the increasingly competitive pancreatic cancer space.
James Waldron Oct 26, 2026 9:45am
tango dancers dancing

Tango trims headcount after showcasing RevMed combo's potential

Oct 26, 2026 5:06am
Photo of a person celebrating at the top of the mountain while the sun setsrises

Verastem CEO says RAS drug 'set new benchmark' for tricky cancer

Oct 14, 2026 10:27am
Podcast
Promotional graphic for The Top Line featuring a microscope molecular model and laboratory glassware against a blue gr

The future of RAS inhibitors

Sep 11, 2026 9:48am
Revolution Medicines booth at ASCO 2026
Favicon Fierce Pharma

FDA greenlights RevMed’s pancreatic cancer gamechanger

Aug 26, 2026 11:30am
pancreatic cancer pancreas model

Craif raises $33M to boost work on its urine test for cancer

Aug 18, 2026 10:04am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings